HealthStream, Inc. (NASDAQ: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the third quarter ended September 30, 2018. In the following bullet-point highlights, (i) all results are from continuing operations only (i.e., 2017 and 2018 results exclude the gain on the sale of our divested Patient Experience business segment which was completed in February 2018 and the results of operations of such segment prior to this divestiture) and (ii) 2018 results are presented in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers (ASC 606), whereas results for 2017 are presented in accordance with ASC 605.
Financial Results:
Third Quarter 2018 Compared to Third
Quarter 2017
On January 1, 2018, the Company adopted ASC 606
using the modified retrospective approach. Under this approach, prior
period results continue to be presented in accordance with the previous
standard of ASC 605. See discussion elsewhere in this release about
comparisons with respect to our results under ASC 606 and ASC 605.
Revenues for the third quarter of 2018 increased by $5.2 million, or 9 percent, to $59.9 million, compared to $54.7 million for the third quarter of 2017.
| 1 Adjusted EBITDA from continuing operations is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to income from continuing operations and disclosure regarding why we believe adjusted EBITDA from continuing operations provides useful information to investors is included later in this release. |
Revenues from our HealthStream Workforce Solutions segment were approximately $49.1 million for the third quarter of 2018, compared to $44.6 million for the third quarter of 2017. Revenue growth of $4.5 million from our workforce solutions products was primarily a result of an increase in subscription-based product revenues, including higher revenues from our resuscitation and compliance products.
Revenues from our HealthStream Provider Solutions segment were approximately $10.8 million for the third quarter of 2018, compared to $10.1 million for the third quarter of 2017. Revenue growth of $657,000, net of related deferred revenue write-downs, was primarily a result of professional services revenues from Morrisey Associates, Inc. (MAI), which we acquired in August 2016.
Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue balances as part of “fair value” accounting as defined by GAAP. During the third quarter of 2018, HealthStream reported a reduction of $703,000 to operating income and a reduction of $519,000 to net income as a result of deferred revenue write-downs from prior acquisitions. During the third quarter of 2017, HealthStream reported a reduction of $146,000 to operating income and a reduction of $87,000 to net income as a result of deferred revenue write-downs from prior acquisitions. The table reconciling GAAP to non-GAAP financial measures included in this release shows the impact of beginning balance deferred revenue write-downs on operating income and net income during the three and nine months ended September 30, 2018 and 2017.
Operating income was $4.7 million for the third quarter of 2018, up 71 percent from $2.7 million for the third quarter of 2017. Operating income was positively impacted by the increase in revenue and by the application of ASC 606 as noted above. The positive impact of these items on operating income was partially offset by higher operating expenses associated with increased royalties, amortization, and personnel costs and by the increased amount of deferred revenue write-downs in the third quarter of 2018 compared to the 2017 period.
Income from continuing operations was $3.0 million in the third quarter of 2018, up 75 percent from $1.7 million in the third quarter of 2017. Income from continuing operations was positively impacted by the increase in revenue and the application of ASC 606 as noted above, partially offset by a decline in fair value of a minority equity investment accounted for under the cost method of accounting of $938,000, net of tax, and the increased amount of deferred revenue write-downs in the third quarter of 2018 compared to the 2017 period. EPS from continuing operations was $0.09 per share (diluted) in the third quarter of 2018, compared to $0.06 per share (diluted) for the third quarter of 2017.
Net income (from continuing and discontinued operations) was $3.0 million in the third quarter of 2018, compared to $2.5 million in the third quarter of 2017. Earnings per share (diluted) were $0.09 per share for the third quarter of 2018, compared to $0.08 per share (diluted) for the third quarter of 2017.
Adjusted EBITDA from continuing operations increased to $11.1 million for the third quarter of 2018, compared to $9.1 million for the third quarter of 2017. The application of ASC 606 had a positive impact of $1.1 million on Adjusted EBITDA from continuing operations during the third quarter of 2018.
Adjusted EBITDA (from continuing and discontinued operations) was $11.1 million for the third quarter of 2018, compared to $11.0 million for the third quarter of 2017.
At September 30, 2018, the Company had cash and cash equivalents and marketable securities of $174.3 million. Capital expenditures incurred during the third quarter of 2018 were approximately $4.1 million.
At September 30, 2018, we had approximately 4,827,000 total subscribers implemented to use and 4,852,000 total subscribers contracted to use our subscription-based solutions. “Contracted subscribers” include both those already implemented and those under contract that are in the process of implementation. Revenue recognition generally commences when a contract is implemented.
Year-to-Date 2018 Compared to Year-to-Date 2017
For the
first nine months of 2018, revenues were $171.8 million, an increase of
8 percent over revenues of $159.6 million for the first nine months of
2017. Revenue increased in the amount of $12.2 million, which was
partially offset by a decline in ICD-10 readiness revenue of $905,000.
Operating income for the first nine months of 2018 increased by 60
percent to $12.7 million, compared to $7.9 million for the first nine
months of 2017. Income from continuing operations for the first nine
months of 2018 increased by 82 percent to $10.3 million, compared to
$5.7 million for the first nine months of 2017. Earnings per share from
continuing operations were $0.32 per share (diluted) for the first nine
months of 2018, compared to $0.18 per share (diluted) for the first nine
months of 2017. Net income for the first nine months of 2018 increased
to $29.4 million, compared to $6.1 million for the first nine months of
2017, which increase was primarily driven by the $19.1 million gain, net
of tax, on the sale of the PX business as noted below. Earnings per
share were $0.91 per share (diluted) for the first nine months of 2018,
compared to $0.19 per share (diluted) for the first nine months of 2017.
Adjusted EBITDA from continuing operations increased by 19 percent to
$32.1 million for the first nine months of 2018, compared to $27.0
million for the first nine months of 2017. Adjusted EBITDA increased to
$61.6 million for the first nine months of 2018, compared to $29.5
million for the first nine months of 2017, which increase was primarily
driven by the pre-tax gain on the sale of the PX business of $29.5
million.
Financial Impact of Adopting ASC 606
The chart on page
eleven under the heading of “Impact of Adoption of ASC 606” sets forth
what the revenues, operating income, net income from continuing
operations, adjusted EBITDA from continuing operations, and non-GAAP
operating income would have been for the third quarter of 2018 and first
nine months of 2018 if the prior revenue recognition standard was
applied (ASC 605).
2018 Events
On February 12, 2018, the Company divested its
Patient Experience (PX) business to Press Ganey Associates for $65.5
million in cash (without giving effect to the post-closing working
capital adjustment). HealthStream recorded a gain, net of tax, on the
sale of its PX business of $19.1 million. The sale of the PX business
resulted in the Company’s complete divestiture of the Company’s patient
experience solutions business segment. With the proceeds from this
transaction, the Board of Directors declared a $1.00 per common share
special cash dividend which was paid on April 3, 2018 to shareholders of
record on March 6, 2018.
Management Team Announcements
HealthStream’s Chief Financial
Officer, Gerard M. Hayden, Jr., has tendered his resignation, which will
be effective following the Company’s filing of Form 10-K for the
full-year 2018, which we expect to occur in March 2019. Afterwards, he
will remain available to HealthStream as a Senior Executive Advisor. The
Board of Directors will oversee the process to fill the CFO position.
To ensure a smooth transition following Mr. Hayden’s departure as CFO, Scott A. Roberts, HealthStream’s Vice President, Accounting & Finance, will serve as Interim CFO. Mr. Roberts, who is a Certified Public Accountant, joined HealthStream 16 years ago after working at Ernst & Young. His broad experience in public financial reporting and deep knowledge of financial operations, both in general and Company-specific terms, makes him particularly qualified to serve as an Interim CFO and as a candidate to fill the position permanently.
Financial Outlook for 2018
The Company adopted the new
revenue recognition standard (ASC 606) utilizing the modified
retrospective approach effective January 1, 2018, such that the Company
has recognized revenue under this new standard for periods beginning on
and after January 1, 2018, but will continue to report results for
periods prior to January 1, 2018 under the prior revenue recognition
standard (ASC 605). To assist in providing comparability against
2017 results, the Company will continue to disclose certain financial
information for 2018 under ASC 605 in the notes to financial statements
to be included in Forms 10-Q and 10-K for 2018.
The historical financial results of the PX business for periods prior to the closing of this transaction are reflected in the Company’s consolidated financial statements as discontinued operations. Accordingly, this financial outlook for 2018 is for continuing operations only and does not include (a) the gain on the sale of our PX business, which we completed on February 12, 2018, or (b) the results of our PX business during 2017, or the period in 2018 prior to the sale of such business, for this financial outlook.
Consistent with our most recent earnings release issued on July 23, 2018, we are presenting our updated 2018 financial outlook utilizing ASC 606 with respect to our anticipated 2018 results in light of the fact that our 2018 results are being presented under ASC 606.
For 2018, we continue to anticipate that consolidated revenues will increase six to eight percent as compared to 2017. We continue to anticipate that revenue growth in our Workforce Solutions segment will be in the four to six percent range and our Provider Solutions segment to grow 10 to 20 percent when compared to 2017.
We anticipate operating income for 2018 to increase between 45 and 60 percent as compared to 2017.
We anticipate that capital expenditures will be approximately $19 million during 2018. We expect the annual effective income tax rate to range between 20 and 22 percent for 2018.
This guidance does not include the impact of any acquisitions or strategic investments that we may complete during 2018.
“As our CFO for the last decade and as a board member for two years prior to that, Gerry Hayden has served the Company extraordinarily well and his leadership has been instrumental in the Company’s growth,” said Robert A. Frist, Jr., Chief Executive Officer. “Gerry has been and will continue for the next several months to be a valuable member of our executive team. The standard he has set is one of the utmost integrity and commitment. We are grateful for his service and wish him success in whatever future endeavors he chooses to pursue.”
A conference call with Robert A. Frist, Jr., Chief Executive Officer, Gerard M. Hayden, Jr., Senior Vice President and Chief Financial Officer, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, October 23, 2018, at 9:00 a.m. (ET). To listen to the conference, please dial 877-647-2842 (no conference ID needed) if you are calling within the domestic U.S. or Canada. If you are an international caller, please dial 914-495-8564 (no conference ID needed). The conference may also be accessed by going to http://ir.healthstream.com/events.cfm for the simultaneous Webcast of the call, which will subsequently be available for replay. The replay telephone numbers are 855-859-2056 (conference ID #1996878) for U.S. and Canadian callers and 404-537-3406 (conference ID #1996878) for international callers.
Use of Non-GAAP Financial Measures
This press release
contains certain non-GAAP financial measures, including non-GAAP net
income, non-GAAP operating income, adjusted EBITDA from continuing
operations, and adjusted EBITDA, which are used by management in
analyzing the Company’s financial results and ongoing operational
performance.
In order to better assess the Company’s financial results, management believes that net income before interest, income taxes, share-based compensation, depreciation and amortization, and changes in fair value of cost method investments (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain non-cash and non-operating items. Effective January 1, 2018, the Company adopted ASU 2016-01, which (among other things) requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. During the three months ended September 30, 2018, the Company recorded a reduction to net income and net income from continuing operations from a change in the fair value of a minority equity investment accounted for under the cost method of accounting. The Company has included this adjustment in the calculation of adjusted EBITDA, and intends to continue to include any positive or negative changes in fair value of cost method investments in the calculation of adjusted EBITDA on a prospective basis, because management believes that such changes do not represent the ongoing operational performance of the Company. Management also believes that adjusted EBITDA from continuing operations is a useful measure for evaluating the operating performance of the Company because such measure excludes the results of operations of the PX business that we no longer own and thus reflects the Company’s ongoing business operations and assists in comparing the Company’s results of operations between periods. We also believe that adjusted EBITDA and adjusted EBITDA from continuing operations are useful to many investors to assess the Company’s ongoing results from current operations. Adjusted EBITDA and adjusted EBITDA from continuing operations are non-GAAP financial measures and should not be considered as measures of financial performance under GAAP. Because adjusted EBITDA and adjusted EBITDA from continuing operations are not measurements determined in accordance with GAAP, such non-GAAP financial measures are susceptible to varying calculations. Accordingly, adjusted EBITDA and adjusted EBITDA from continuing operations, as presented, may not be comparable to other similarly titled measures of other companies.
In recent years, the Company has acquired businesses whose net tangible assets include deferred revenue. In accordance with GAAP reporting requirements, following the completion of any such acquisition, the Company may record a write-down of deferred revenue to fair value as defined by GAAP. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods.
In connection therewith, this release presents below non-GAAP operating income and non-GAAP net income, which in each case reflects the corresponding GAAP figures adjusted to exclude the impact of the deferred revenue write-down associated with fair value accounting for acquired businesses as referenced above. Management believes that the presentation of these non-GAAP financial measures assists investors in understanding the Company’s performance between periods, excluding the impact of this deferred revenue write-down, and provides a useful measure of the ongoing performance of the Company. Both on a quarterly and year-to-date basis, the revenue for any acquired business is deferred and typically recognized over a one-to-two year period following the completion of an acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue had not been written down to fair value.
These non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review the reconciliations of our GAAP to non-GAAP financial measures, which are set forth below in this release.
About HealthStream
HealthStream (NASDAQ: HSTM) is dedicated
to improving patient outcomes through the development of healthcare
organizations’ greatest asset: their people. Our unified suite of
solutions is contracted by, collectively, approximately 4.9 million
healthcare employees in the U.S. for workforce development, training &
learning management, talent management, credentialing, privileging,
provider enrollment, performance assessment, and managing
simulation-based education programs. Based in Nashville, Tennessee,
HealthStream has additional offices in Brentwood, Tennessee; Jericho,
New York; Boulder; Colorado; San Diego, California; and Chicago,
Illinois. For more information, visit http://www.healthstream.com
or call 800-933-9293.
|
HEALTHSTREAM, INC. Condensed Consolidated Statements of Income (In thousands, except per share data) |
||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||
|
September 30, |
September 30, |
September 30, |
September 30, |
|||||||||||||||
| Revenues, net | $ | 59,925 | $ | 54,743 | $ | 171,791 | $ | 159,630 | ||||||||||
| Operating costs and expenses: | ||||||||||||||||||
| Cost of revenues (excluding depreciation and amortization) | 25,102 | 22,523 | 70,586 | 64,898 | ||||||||||||||
| Product development | 6,600 | 6,002 | 19,149 | 17,929 | ||||||||||||||
| Sales and marketing | 8,559 | 9,145 | 26,536 | 27,764 | ||||||||||||||
| Other general and administrative expenses | 8,997 | 8,371 | 24,769 | 23,269 | ||||||||||||||
| Depreciation and amortization | 6,006 | 5,971 | 18,097 | 17,874 | ||||||||||||||
| Total operating costs and expenses | 55,264 | 52,012 | 159,137 | 151,734 | ||||||||||||||
| Operating income | 4,661 | 2,731 | 12,654 | 7,896 | ||||||||||||||
| Other (loss) income, net | (548 | ) | 186 | 241 | 481 | |||||||||||||
| Income from continuing operations before income tax provision | 4,113 | 2,917 | 12,895 | 8,377 | ||||||||||||||
| Income tax provision | 1,077 | 1,182 | 2,575 | 2,709 | ||||||||||||||
| Income from continuing operations | 3,036 | 1,735 | 10,320 | 5,668 | ||||||||||||||
| Discontinued operations | ||||||||||||||||||
| Income (loss) from discontinued operations before income tax provision | — | 1,238 | (64 | ) | 762 | |||||||||||||
| Gain on sale of discontinued operations | — | — | 29,490 | — | ||||||||||||||
| Income tax provision | — | 469 | 10,319 | 374 | ||||||||||||||
| Income from discontinued operations | — | 769 | 19,107 | 388 | ||||||||||||||
| Net Income | $ | 3,036 | $ | 2,504 | $ | 29,427 | $ | 6,056 | ||||||||||
| Earnings per share – basic: | ||||||||||||||||||
| Continuing operations | $ | 0.09 | $ | 0.06 | $ | 0.32 | $ | 0.18 | ||||||||||
| Discontinued operations | — | 0.02 | 0.59 | 0.01 | ||||||||||||||
| Earnings per share - basic | $ | 0.09 | $ | 0.08 | $ | 0.91 | $ | 0.19 | ||||||||||
| Earnings per share - diluted: | ||||||||||||||||||
| Continuing operations | $ | 0.09 | $ | 0.06 | $ | 0.32 | $ | 0.18 | ||||||||||
| Discontinued operations | — | 0.02 | 0.59 | 0.01 | ||||||||||||||
| Earnings per share - diluted | $ | 0.09 | $ | 0.08 | $ | 0.91 | $ | 0.19 | ||||||||||
| Weighted average shares of common stock outstanding: | ||||||||||||||||||
| Basic | 32,322 | 31,893 | 32,244 | 31,848 | ||||||||||||||
| Diluted | 32,415 | 32,217 | 32,308 | 32,183 | ||||||||||||||
| Dividends declared per share | $ | — | $ | — | $ | 1.00 | $ | — | ||||||||||
|
HEALTHSTREAM, INC. Condensed Consolidated Balance Sheets (In thousands) |
||||||||||
| September 30, | December 31, | |||||||||
| 2018 |
2017(1) |
|||||||||
| ASSETS | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 130,283 | $ | 84,768 | ||||||
| Marketable securities | 44,025 | 46,350 | ||||||||
| Accounts and unbilled receivables, net | 31,432 | 38,018 | ||||||||
| Prepaid and other current assets | 24,919 | 24,467 | ||||||||
| Current assets of discontinued operations | — | 6,125 | ||||||||
| Total current assets | 230,659 | 199,728 | ||||||||
| Capitalized software development, net | 16,770 | 16,014 | ||||||||
| Property and equipment, net | 8,683 | 8,092 | ||||||||
| Goodwill and intangible assets, net | 147,794 | 154,641 | ||||||||
| Deferred tax assets | — | 45 | ||||||||
| Deferred commissions | 13,474 | — | ||||||||
| Other assets | 4,120 | 4,526 | ||||||||
| Long-term assets of discontinued operations | — | 28,073 | ||||||||
| Total assets | $ | 421,500 | $ | 411,119 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable, accrued and other liabilities | $ | 35,358 | $ | 29,356 | ||||||
| Deferred revenue | 62,151 | 64,938 | ||||||||
| Current liabilities of discontinued operations | — | 6,772 | ||||||||
| Total current liabilities | 97,509 | 101,066 | ||||||||
| Deferred tax liabilities | 5,082 | — | ||||||||
| Deferred revenue, non-current | 2,333 | 6,287 | ||||||||
| Other long-term liabilities | 882 | 1,048 | ||||||||
| Long-term liabilities of discontinued operations | — | 2,548 | ||||||||
| Total liabilities | 105,806 | 110,949 | ||||||||
| Shareholders’ equity: | ||||||||||
| Common stock | 286,128 | 282,666 | ||||||||
| Accumulated other comprehensive loss | (17 | ) | (38 | ) | ||||||
| Retained earnings | 29,583 | 17,542 | ||||||||
|
Total shareholders’ equity |
315,694 | 300,170 | ||||||||
|
Total liabilities and shareholders’ equity |
$ | 421,500 | $ | 411,119 | ||||||
|
(1) |
Derived from audited financial statements contained in the Company’s filing on Form 10-K for the year ended December 31, 2017, adjusted for the divestiture of the PX business segment. | |
|
HEALTHSTREAM, INC. Condensed Consolidated Statements of Cash Flows (In thousands) |
||||||||||
| Nine Months Ended | ||||||||||
| September 30, | September 30, | |||||||||
| 2018 | 2017 | |||||||||
| Operating activities: | ||||||||||
| Net income | $ | 29,427 | $ | 6,056 | ||||||
| Income from discontinued operations | (19,107 | ) | (388 | ) | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation and amortization | 18,097 | 17,874 | ||||||||
| Share-based compensation | 1,306 | 1,241 | ||||||||
| Deferred income taxes | 661 | 710 | ||||||||
| Provision for doubtful accounts | 690 | 820 | ||||||||
| (Gain) loss on equity method investments | (25 | ) | 5 | |||||||
| Change in fair value of cost method investments | 1,271 | — | ||||||||
| Other | (22 | ) | 351 | |||||||
| Changes in assets and liabilities: | ||||||||||
| Accounts and unbilled receivables | 5,865 | 4,422 | ||||||||
| Prepaid and other assets | (1,441 | ) | 885 | |||||||
| Accounts payable, accrued and other liabilities | (7,576 | ) | 1,841 | |||||||
| Deferred revenue | 658 | (1,464 | ) | |||||||
| Net cash provided by continuing operating activities | 29,804 | 32,353 | ||||||||
| Net cash (used in) provided by discontinued operating activities | (1,003 | ) | 3,310 | |||||||
| Net cash provided by operating activities | 28,801 | 35,663 | ||||||||
| Investing activities: | ||||||||||
| Proceeds from sale of discontinued operations | 57,827 | — | ||||||||
| Changes in marketable securities | 2,367 | (9,724 | ) | |||||||
| Payments to acquire cost method investments | (833 | ) | (500 | ) | ||||||
| Purchases of property and equipment | (4,342 | ) | (4,828 | ) | ||||||
| Payments associated with capitalized software development | (8,042 | ) | (7,480 | ) | ||||||
| Net cash provided by (used in) continuing investing activities | 46,977 | (22,532 | ) | |||||||
| Net cash used in discontinued investing activities | (115 | ) | (2,217 | ) | ||||||
| Net cash provided by (used in) investing activities | 46,862 | (24,749 | ) | |||||||
| Financing activities: | ||||||||||
| Proceeds from exercise of stock options | 2,582 | 322 | ||||||||
| Taxes paid related to net settlement of equity awards | (335 | ) | (410 | ) | ||||||
| Payment of earn-outs related to prior acquisitions | (38 | ) | — | |||||||
| Payment of cash dividends | (32,357 | ) | — | |||||||
| Net cash used in continuing financing activities | (30,148 | ) | (88 | ) | ||||||
| Net cash used in discontinued financing activities | — | — | ||||||||
| Net cash used in financing activities | (30,148 | ) | (88 | ) | ||||||
| Net increase in cash and cash equivalents | 45,515 | 10,826 | ||||||||
| Cash and cash equivalents at beginning of period | 84,768 | 49,634 | ||||||||
| Cash and cash equivalents at end of period | $ | 130,283 | $ | 60,460 | ||||||
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) (In thousands) |
||||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| GAAP income from continuing operations | $ | 3,036 | $ | 1,735 | $ | 10,320 | $ | 5,668 | ||||||||||||
| Interest income | (736 | ) | (221 | ) | (1,586 | ) | (583 | ) | ||||||||||||
| Interest expense | 32 | 35 | 98 | 97 | ||||||||||||||||
| Income tax provision | 1,077 | 1,182 | 2,575 | 2,709 | ||||||||||||||||
| Stock based compensation expense | 459 | 401 | 1,306 | 1,241 | ||||||||||||||||
| Depreciation and amortization | 6,006 | 5,971 | 18,097 | 17,874 | ||||||||||||||||
| Change in fair value of cost method investments | 1,271 | — | 1,271 | — | ||||||||||||||||
| Adjusted EBITDA from continuing operations | $ | 11,145 | $ | 9,103 | $ | 32,081 | $ | 27,006 | ||||||||||||
| GAAP net income | $ | 3,036 | $ | 2,504 | $ | 29,427 | $ | 6,056 | ||||||||||||
| Interest income | (736 | ) | (221 | ) | (1,586 | ) | (583 | ) | ||||||||||||
| Interest expense | 32 | 35 | 98 | 97 | ||||||||||||||||
| Income tax provision | 1,077 | 1,651 | 12,894 | 3,083 | ||||||||||||||||
| Stock based compensation expense | 459 | 440 | 1,215 | 1,358 | ||||||||||||||||
| Depreciation and amortization | 6,006 | 6,570 | 18,279 | 19,488 | ||||||||||||||||
| Change in fair value of cost method investments | 1,271 | — | 1,271 | — | ||||||||||||||||
| Adjusted EBITDA | $ | 11,145 | $ | 10,979 | $ | 61,598 | $ | 29,499 | ||||||||||||
| GAAP operating income | $ | 4,661 | $ | 2,731 | $ | 12,654 | $ | 7,896 | ||||||||||||
| Adjustment for deferred revenue write-down | 703 | 146 | 779 | 1,539 | ||||||||||||||||
| Non-GAAP operating income | $ | 5,364 | $ | 2,877 | $ | 13,433 | $ | 9,435 | ||||||||||||
| GAAP net income | $ | 3,036 | $ | 2,504 | $ | 29,427 | $ | 6,056 | ||||||||||||
| Adjustment for deferred revenue write-down, net of tax | 519 | 87 | 583 | 1,077 | ||||||||||||||||
| Non-GAAP net income | $ | 3,555 | $ | 2,591 | $ | 30,010 | $ | 7,133 | ||||||||||||
|
(1) |
This press release contains certain non-GAAP financial measures, including non-GAAP net income, non-GAAP operating income, adjusted EBITDA, and adjusted EBITDA from continuing operations, which are used by management in analyzing its financial results and ongoing operational performance. | |
|
Impact of Adoption of ASC 606 |
||||||||||||||||
|
Three Months Ended September 30, |
||||||||||||||||
| 2018 | 2017 | |||||||||||||||
|
ASC 606 As reported |
Adjustments from ASC 606 to ASC 605 |
ASC 605 As adjusted |
ASC 605 | |||||||||||||
| Revenue | $ | 59,925 | $ | 634 | $ | 59,291 | $ | 54,743 | ||||||||
| Operating income | 4,661 | 1,109 | 3,552 | 2,731 | ||||||||||||
| Income from continuing operations | 3,036 | 819 | 2,217 | 1,735 | ||||||||||||
| Adjusted EBITDA from continuing operations | 11,145 | 1,109 | 10,036 | 9,103 | ||||||||||||
| Non-GAAP operating income | 5,364 | 1,109 | 4,255 | 2,877 | ||||||||||||
|
Nine Months Ended |
|||||||||||||
| 2018 | 2017 | ||||||||||||
|
ASC 606 |
Adjustments |
ASC 605 |
ASC 605 | ||||||||||
| Revenue | $ | 171,791 | $ | 738 | $ | 171,053 | $ | 159,630 | |||||
| Operating income | 12,654 | 2,506 | 10,148 | 7,896 | |||||||||
| Income from continuing operations | 10,320 | 2,006 | 8,314 | 5,668 | |||||||||
| Adjusted EBITDA from continuing operations | 32,081 | 2,506 | 29,575 | 27,006 | |||||||||
| Non-GAAP operating income | 13,433 | 2,506 | 10,927 | 9,435 | |||||||||
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for the financial performance for 2018, that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, as the result of risks referenced in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed on February 26, 2018, and in the Company’s other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005794/en/
HealthStream, Inc.
Gerard M. Hayden, Jr., 615-301-3163
Chief
Financial Officer
ir@healthstream.com
or
Media:
Mollie
Condra, Ph.D., 615-301-3237
Vice President, Investor Relations &
Communications
mollie.condra@healthstream.com